Navigation Links
ArterX™ Clinical Trial Results Announced at Veith Meeting
Date:11/18/2010

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York.  William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

In a presentation titled "A Novel More Effective Glue-Sealant (ArterX) for Hemostasis at Vascular Suture Lines and Other Sites," Dr. Stone reported that ArterX Surgical Sealant achieved immediate hemostasis more than 60% of the time in a 217 patient clinical trial conducted at 11 different hospitals in the US.

President and CEO, David Smith, commented, "We are delighted with the preliminary results of our US clinical trial.  We were also able to show a statistically significant reduction in operating time of 36 minutes in the ArterX group, and ArterX patients were discharged from hospital after 4.1 days, an improvement of 1.3 days over the control group. If approved, we believe that ArterX Surgical Sealant will yield economic benefits for surgeons and hospitals that adopt it."

ArterX Surgical Sealant is currently under review by the FDA and is not available for sale in the USA.

ArterX is CE Marked in the European Union

About Tenaxis Medical, Inc.

Incorporated in 2004 and located in Mountain View, CA, Tenaxis Medical, Inc. is a privately held Company. It develops novel, high performance sealants for use in vascular and general surgery. In addition to the ArterX Surgical Sealant, the company is developing a second high performance sealant for use throughout the gastrointestinal tract, and an anti-adhesion agent that can be delivered  laparoscopically to help prevent or reduce pelvic and abdominal adhesions.Contact: Ronald Dieck+1-650-691-9016, ext. 110
'/>"/>

SOURCE Tenaxis Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
2. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Clinical Experts Describe Radiosurgical Advances for Brain, Breast, and Spinal Cancers
5. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
6. PAREXEL Wins Clinical Research Team of the Year Scrip Award
7. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
10. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... TOKYO , March 29, 2017  The ... unique Japanese public-private partnership formed to battle infectious ... investments totaling US$23 million* that could help deliver ... host of debilitating conditions. This ... a Phase 3 clinical trial testing a pediatric ...
(Date:3/29/2017)... leader in accelerated orthodontics, OrthoAccel ® Technologies, Inc. ... Manal Ibrahim , Kenji Ojima , Ivan ... microlecture presenters at the AcceleDent ® booth (#3037) ... Session, April 21-25, 2017. Orthodontists and their staff are ... a.m. On the opening morning of AAO exhibitions, Sat., ...
(Date:3/29/2017)... 2017 Transparency Market Research ... an exhaustive study of the U.S. substance abuse treatment ... are functional in this market at present, making ... companies, such as GlaxoSmithKline Plc., Pfizer Inc., Alkermes ... various marketing strategies to increase their visibility, the ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... This morning, more than 275 medical ... support for an independent Vaccine Safety Commission. Five of the signers of the ... hold a press conference at 9:00 AM Friday, March 31 at the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale price ... the remaining days of March, the price will be only $19.97. The EXOUS Bodygear ... just $10 (regular retail price $19.97). , The special promotional prices are to help ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
Breaking Medicine News(10 mins):